BioMarin to Hold Conference Call Today, May 16, at 12:00 PM EDT (18:00 CEST) to Discuss Recent Company Developments and First Quarter 2005 Financial Results
May 16, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the company will host a conference call today, Monday, May 16, 2005, at 12:00 p.m. EDT (18:00 CEST), to discuss recent company developments and financial results from the first quarter of 2005. The call will be broadcast live over the internet and available on the investor section of the BioMarin website, http://www.bmrn.com/.
What: BioMarin Conference Call to Discuss Recent Company Developments and First Quarter 2005 Financial Results Date: Monday, May 16, 2005 Time: 12:00 p.m. EDT (18:00 CEST) Dial in Numbers: U.S. & Canada Toll-free Dial in #: 800.299.9086 International Dial in #: 617.786.2903 Participant Code: 69323515 Replay Toll-free Dial in #: 888.286.8010 Replay International Dial in #: 617.801.6888 Replay Code: 30154746 Webcast: Investor section of http://www.bmrn.com/ About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I) and Orapred(R) (prednisolone sodium phosphate oral solution) for severe asthma, and multiple investigational product candidates including rhASB (galsulfase), a BLA/MAA-stage product candidate under regulatory review for the treatment of mucopolysaccharidosis VI (MPS VI), and Phenoptin(TM) (sapropterin hydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit http://www.bmrn.com/. Information on BioMarin's website is not incorporated by reference into this press release.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.
Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.
Contact: Investors Media Joshua A. Grass Susan Ferris BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6777 (415) 506-6701
SOURCE: BioMarin Pharmaceutical Inc.
CONTACT: Investors: Joshua A. Grass, +1-415-506-6777, Media: Susan
Ferris, +1-415-506-6701, both of BioMarin Pharmaceutical Inc.
Web site: http://www.bmrn.com/